Hematologist
CION Cancer Clinics
Germinal centre vs non-germinal centre DLBCL | CION Cancer Clinics
GCB and ABC (often reported as non-GCB) name the kind of B cell a diffuse large B-cell lymphoma grew from. Both are aggressive and both are usually treated first with R-CHOP or a close variant. The subtype helps your haematologist read the full picture, but on its own it does not decide your treatment or your outlook. Here is how to read it. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What do GCB and ABC mean on a DLBCL report?
- Which words on the report tell you the subtype?
- How is the subtype actually worked out?
- How do GCB and non-GCB DLBCL differ?
- Does the subtype change the treatment you are offered?
- What do families often get wrong about the subtype?
- What should you do with this result?
- Common questions about GCB and non-GCB DLBCL
The short answer
What do GCB and ABC mean on a DLBCL report?
GCB and ABC describe which kind of normal B cell the lymphoma grew from. GCB stands for germinal centre B-cell. ABC stands for activated B-cell, and most Indian laboratories report it as "non-GCB". Both are diffuse large B-cell lymphoma (DLBCL), and both are usually treated the same way at the start.
Where the two names come from
B cells are the white blood cells that make antibodies. Inside a lymph node, they pass through a busy area called the germinal centre, where they learn to recognise germs. A lymphoma can start from a cell still inside that area, or from a cell that has already left it and switched on. The lab calls this the "cell of origin".
Why doctors bother to test for it
The two groups behave a little differently. They switch on different growth signals, and they can respond differently to some newer medicines. So the subtype helps your haematologist read the whole picture. It is one piece of information, alongside the stage, your blood tests, your age and your general fitness.
What it does not decide on its own
The subtype does not tell you how your own treatment will go. Two people with the same label can have very different courses. Treat it as a line on the report to ask about, not as a verdict.
If your report says only "DLBCL" with no subtype, ask whether the test was done. It is usually possible on the same biopsy block.On your report
Which words on the report tell you the subtype?
- Cell of origin
- The normal B cell the lymphoma most looks like. The answer is GCB, non-GCB or ABC, and sometimes "unclassified".
- Immunohistochemistry (IHC)
- A stain applied to thin slices of your biopsy. Each stain shows whether the cells carry a particular protein.
- CD10, BCL6 and MUM1
- The three proteins most labs stain for to decide the subtype. The report lists each as positive or negative.
- Hans algorithm
- A simple decision chart that turns those three stain results into a GCB or non-GCB label. It is the method used most often in India.
- Gene expression profiling
- A more detailed test that reads which genes are switched on. It is the reference method, but it is not widely available.
How the lab decides
How is the subtype actually worked out?
There are two routes. Almost every report you will see in Hyderabad comes from the first one.
Stains on the biopsy
The pathologist uses the same tissue block that made the diagnosis. The stains are read under a microscope and put through the Hans chart. It is quick, affordable and done in most cancer pathology labs.
Its limits
- It sorts into two groups, not three
- Different labs can read borderline stains differently
- It is a close estimate, not an exact match
Gene expression testing
This reads the activity of many genes at once from the tumour. It separates GCB, ABC and an unclassified group more precisely. It is mostly used in research and in a few specialist laboratories.
Not having this test does not mean your care is incomplete. Treatment decisions today do not depend on it.Tests that often come alongside
The same report may mention MYC, BCL2 and BCL6. Those are separate questions about gene changes, tested by a method called FISH. They matter more than the subtype for some treatment choices.
Look for
- "Double expressor" in the stain section
- "Double hit" or "triple hit" in a FISH report
Not sure whether this applies to you?
Ask an oncologistSide by side
How do GCB and non-GCB DLBCL differ?
Germinal centre (GCB)
Non-germinal centre (non-GCB or ABC)
Grew from a B cell still inside the germinal centre
Grew from a B cell that had left and become activated
CD10 is usually positive on the stains
MUM1 is usually positive and CD10 negative
On average, tends to respond well to standard first treatment
On average, has a somewhat higher chance of coming back
More often linked with MYC and BCL2 gene changes
More often driven by constant "on" signals inside the cell
First treatment is usually R-CHOP or a close variant
First treatment is also usually R-CHOP or a close variant
What it means for the plan
Does the subtype change the treatment you are offered?
For first treatment, mostly not. Both subtypes are usually started on rituximab-based chemotherapy such as R-CHOP. Trials that added extra drugs only for the ABC group have not changed routine practice for most people.
Where it can make a difference
Some newer options, such as polatuzumab combined with R-CHP, have been studied across both subtypes. Your team may weigh the subtype when choosing between them. If the lymphoma comes back later, the subtype can also guide which trial or second-line medicine is worth considering.
Who this information does not help much
If you are older or frailer and a gentler plan is being discussed, the subtype rarely changes that choice. Fitness, kidney and heart function and other illnesses matter more. The same applies if the lymphoma sits in the brain, which is handled as a separate condition.
What this page cannot tell you
It cannot read your report or give you an outlook. The subtype, the IPI score and the scans are put together by the treating haematologist. Ask them how each finding shaped the plan they are recommending.
Commonly believed
What do families often get wrong about the subtype?
"Non-GCB means the treatment will not work."
That is not what the label means. Many people with non-GCB lymphoma respond well to first treatment and stay well. The subtype shifts an average across large groups. It does not decide what happens to one person.
"We should wait for the gene test before starting."
DLBCL is a fast-growing lymphoma. Delaying treatment to chase a test that rarely changes the first plan can cause real harm. Ask your haematologist whether any pending result would change the plan before agreeing to wait.
"GCB means it is the mild kind."
Both subtypes are aggressive lymphomas that need prompt treatment. GCB lymphomas can still carry high-risk gene changes such as a double hit. Reassurance should come from the full report, not one word.
"A second lab will give a better subtype."
A review by an experienced lymphoma pathologist is sensible when the diagnosis itself is uncertain. Sending blocks around only to change GCB to non-GCB usually adds cost and delay without changing treatment.
Your next move
What should you do with this result?
Find the subtype line
Look in the immunohistochemistry section of the biopsy report. Note whether it says GCB, non-GCB or ABC, and whether a FISH report is attached.
Gather the rest of the picture
Bring the PET-CT, blood tests including LDH, and any bone marrow report. The subtype only makes sense next to these.
Ask three questions
Did the subtype change your recommendation? Was FISH testing done or needed? Is there a trial or newer option that fits this subtype?
Start without undue delay
Once the plan is clear, begin. A tumour board review, where several specialists read the case together, can happen quickly alongside.
Questions we are asked
Common questions about GCB and non-GCB DLBCL
Is ABC the same as non-GCB?
Nearly, but not exactly. ABC is the group found by gene expression testing. Non-GCB is the group found by stains using the Hans chart. The non-GCB group includes most ABC lymphomas plus some that gene testing would call unclassified. In everyday reports in India, the two terms are used almost interchangeably.
Which subtype is worse?
Across large studies, the ABC or non-GCB group has had a somewhat higher chance of relapse after standard treatment. That is an average. Your own outlook depends far more on stage, the IPI score, gene changes, fitness and how the lymphoma responds. Your haematologist can explain how these fit together for you.
My report does not mention GCB at all. Is something missing?
Possibly. Some labs report the stains without naming the subtype, or skip it when the tissue sample is small. Ask your haematologist whether CD10, BCL6 and MUM1 were stained. If they were not, the test can usually be added on the same block without a new biopsy.
Can the subtype change over time?
The cell of origin usually stays the same. If the lymphoma comes back, a fresh biopsy is often taken to confirm it is the same disease and to look for new gene changes. That repeat biopsy may be read again for subtype, and occasionally the result looks different.
Does GCB or non-GCB affect whether I need a transplant?
Not at the start. Stem cell transplant or CAR-T is usually discussed only if the lymphoma does not respond or comes back. At that stage, timing of relapse, response to further treatment and fitness count for more than the subtype. CION's team coordinates such referrals with qualified transplant centres.
Is gene expression profiling worth paying for?
For most people, it does not change the first plan, so it is rarely needed. It may be useful if you are joining a clinical trial that selects by subtype. Ask your haematologist whether the result would change any decision before arranging it privately.
What does "double expressor" mean next to the subtype?
It means the stains show high levels of both the MYC and BCL2 proteins. It is separate from GCB or non-GCB, and is seen more often in non-GCB lymphoma. It is not the same as a double hit, which is a gene change found by FISH testing.
Can a second opinion on the subtype help?
A second opinion is useful if the diagnosis, the stage or the plan is unclear to you. A pathology review can confirm the subtype and check for gene testing that was missed. CION's haematology team reviews reports and presents cases at a tumour board before advising on next steps.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Adult Non-Hodgkin Lymphoma Treatment (PDQ) - Health Professional Version
- Leukemia & Lymphoma Society — Non-Hodgkin Lymphoma
- American Cancer Society — Non-Hodgkin Lymphoma
- Cancer Research UK — Non-Hodgkin lymphoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
MYC, BCL2 and BCL6 Testing in LymphomaThe gene tests that often sit next to the subtypeIPI Score: Predicting DLBCL OutcomeThe risk score your haematologist reads alongside itR-CHOP: The Standard Regimen ExplainedThe usual first treatment for both subtypesAggressive B-Cell LymphomaThe overview of this lymphoma group
Talk to us
Holding a lymphoma report with words you do not follow?
Share it with us. CION's haematology team will go through it with you and explain what each finding means for the next step.